Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Molecular Psychiatry

• Publication date

  2008-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.mp.4002142PMID 18180754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms

  2007cited by this paper
• Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

  2007cited by this paper
• Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.

  2007cited by this paper
• Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17

  2007cited by this paper
• Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long‐term antipsychotic treatment

  2007cited by this paper
• A new era in psychiatric genetics?

  2007cited by this paper
• Is COMT a susceptibility gene for schizophrenia?

  2007cited by this paper
• Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.

  2007cited by this paper
• Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics—a European study

  2007cited by this paper
• [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].

  2006cited by this paper
• Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

  2006cited by this paper
• The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia.

  2006cited by this paper
• Comments on "Association between Ala-9Val polymorphism of MnSOD gene and schizophrenia" by O. Akyol et al. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 2005, 123-131.

  2006cited by this paper
• Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

  2006cited by this paper
• Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

  2006cited by this paper
• Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis

  2006cited by this paper
• Shifting emphasis from pharmacogenomics to theragnostics

  2006cited by this paper
• Neurobiology of schizophrenia.

  2006cited by this paper
• Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.

  2006cited by this paper
• A road map for efficient and reliable human genome epidemiology

  2006cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

  2005cited by this paper
• Polymorphic Variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and Dopamine D2 and D3 Receptors and Their Association With Tardive Dyskinesia in Severe Mental Illness

  2005cited by this paper
• Neuroleptic-induced movement disorders: an overview.

  2005cited by this paper
• Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.

  2005cited by this paper
• CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis

  2005cited by this paper
• Genetics and Epigenetics in Major Psychiatric Disorders

  2005cited by this paper
• The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia.

  2005cited by this paper
• Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.

  2005cited by this paper
• Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.

  2005cited by this paper
• Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia

  2005cited by this paper
• Negative association between Catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia

  2005cited by this paper
• Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients.

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• Clinical implications of pharmacogenomics for tardive dyskinesia

  2004cited by this paper
• Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia

  2004cited by this paper
• Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene.

  2004cited by this paper
• Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.

  2004cited by this paper
• Human Evolutionary Genetics: Origins, Peoples & Disease

  2004cited by this paper
• COMT haplotypes suggest P2 promoter region relevance for schizophrenia

  2004cited by this paper
• Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

  2004cited by this paper
• Pharmacogenetics of psychotropic drug response.

  2004cited by this paper
• Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment.

  2004cited by this paper
• Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

  2004cited by this paper
• Association of Seven Polymorphisms of the D2 Dopamine Receptor Gene with Brain Receptor-Binding Characteristics

  2004cited by this paper
• Contents of The American Journal of Psychiatry

  2004cited by this paper
• Implications for Atypical Antipsychotics in the Treatment of Schizophrenia: Neurocognition Effects and a Neuroprotective Hypothesis

  2004cited by this paper
• Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

  2003cited by this paper
• A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain.

  2003cited by this paper
• Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.

  2003cited by this paper
• D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes

  2003cited by this paper
• Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia

  2003cited by this paper
• The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria.

  2003cited by this paper
• The genetics of schizophrenia: glutamate not dopamine?

  2003cited by this paper
• Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene.

  2003cited by this paper
• Pharmacogenetics of Psychotropic Drugs

  2002cited by this paper
• A highly significant association between a COMT haplotype and schizophrenia.

  2002cited by this paper
• Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

  2002cited by this paper
• Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia

  2002cited by this paper
• The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

  2002cited by this paper
• Pharmacogenomics in schizophrenia: the quest for individualized therapy.

  2002cited by this paper
• Abnormal Movements and Tardive Dyskinesia in Smokers and Nonsmokers with Schizophrenia Genotyped for Cytochrome P450 2D6

  2002cited by this paper
• Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution

  2001cited by this paper
• Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.

  2001cited by this paper
• Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia.

  2001cited by this paper
• Tardive Drug-Induced Extrapyramidal Syndromes

  2000cited by this paper
• Neurobiology of schizophrenia

  2000cited by this paper
• Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia

  2000cited by this paper
• Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

  2000cited by this paper
• A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

  2000cited by this paper
• Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.

  1999cited by this paper
• Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.

  1999cited by this paper
• Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

  1999cited by this paper
• Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

  1999cited by this paper
• The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers

  1998cited by this paper
• Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.

  1998cited by this paper
• D3 dopamine receptor mRNA is widely expressed in the human brain.

  1998cited by this paper
• D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene

  1998cited by this paper
• D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.

  1997cited by this paper
• Meta-analysis: Principles and procedures

  1997cited by this paper
• A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.

  1997cited by this paper
• Meta-analysis: Potentials and promise

  1997cited by this paper
• Tardive dyskinesia: who is at risk?

  1997cited by this paper
• Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene : a predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease

  1997cited by this paper
• Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

  1997cited by this paper
• Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines.

  1997cited by this paper
• On signal sequence polymorphims and diseases of distribution

  1996cited by this paper
• On signal sequence polymorphisms and diseases of distribution.

  1996cited by this paper
• Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease.

  1996cited by this paper
• Functional Analysis of the Human D2 Dopamine Receptor Missense Variants*

  1996cited by this paper
• A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.

  1996cited by this paper
• Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism.

  1991cited by this paper

• The Burden of Tardive Dyskinesia in Patients with Mental Disorders

  2025cites this paper
• Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial

  2024cites this paper
• Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2

  2024cites this paper
• Epigenome-wide studies of antipsychotics: a systematic review and pathway meta-analysis.

  2023cites this paper
• Associations between Catechol-O-methyltransferase (COMT) polymorphisms and cognitive impairments, psychiatric symptoms and tardive dyskinesia in schizophrenia.

  2023cites this paper
• Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications

  2023cites this paper
• Deep Brain Stimulation in the Treatment of Tardive Dyskinesia

  2023cites this paper
• Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

  2022cites this paper
• Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies

  2022cites this paper
• Pre-prescription testing in psychiatry: An overview

  2022cites this paper
• The Utility of Pharmacogenetics Testing in Psychiatric Populations

  2021cites this paper
• Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies

  2021cites this paper
• Biological Markers Affecting the Efficacy and Safety of Pharmacotherapy in Schizophrenia. Review

  2021cites this paper
• АНАЛИЗ АССОЦИАЦИЙ ФАРМАКОДИНАМИЧЕСКИХ ГЕНЕТИЧЕСКИХ ФАКТОРОВ С ЭФФЕКТИВНОСТЬЮ И БЕЗОПАСНОСТЬЮ АНТИПСИХОТИКОВ У ПОДРОСТКОВ С ОСТРЫМ ПСИХОТИЧЕСКИМ ЭПИЗОДОМ В ТЕЧЕНИЕ 28 ДНЕЙ

  2021cites this paper
• Analysis of associations between pharmacodynamic genetic factors and antipsychotics’ effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up

  2021cites this paper
• Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders

  2021cites this paper
• A unifying theory for the pathoetiologic mechanism of tardive dyskinesia.

  2020cites this paper
• HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia

  2020cites this paper
• Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia

  2020cites this paper
• Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic

  2020influential citation
• Advances in Tardive Dyskinesia : A Review of Recent Literature

  2020cites this paper
• The genetics of drug-related movement disorders, an umbrella review of meta-analyses

  2020influential citation
• Riding the tiger – physiological and pathological effects of superoxide and hydrogen peroxide generated in the mitochondrial matrix

  2020cites this paper
• The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects

  2020cites this paper
• Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia

  2019cites this paper
• Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia

  2019cites this paper
• New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach.

  2019cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Tardive dyskinesia: Who gets it and why.

  2019cites this paper
• University of Groningen Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia Loonen,

  2019cites this paper
• Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.

  2019cites this paper
• The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients

  2019cites this paper
• Tardive dyskinesia: Risk factors, prevention, and treatment

  2019cites this paper
• Classification of psychopathology: conceptual and historical background

  2018cites this paper
• What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Clinical risk factors for the development of tardive dyskinesia.

  2018cites this paper
• Genetics of tardive dyskinesia: Promising leads and ways forward.

  2018cites this paper
• Genome wide study of tardive dyskinesia in schizophrenia

  2018cites this paper
• Pharmakogenetische Einflüsse auf Wirkung und Nebenwirkungen von Antidepressiva und Antipsychotika

  2018influential citation
• Peculiarities of the Effect of Antipsychotics: Pharmacogenetic Studies

  2018cites this paper
• Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly

  2018cites this paper
• Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis

  2018cites this paper
• Management of common adverse effects of antipsychotic medications

  2018cites this paper
• Tardive Dyskinesia : A Review of the Literature

  2017cites this paper
• Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

  2017cites this paper
• Examining the Influence and Role of Pharmacogenetics among Children with Autism Spectrum Disorder

  2017cites this paper
• Pharmacodynamic gene polymorphism and adverse drug reactionsthen applying antipsychotic drugs

  2017cites this paper
• Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.

  2016cites this paper
• Submission Category: Regular Research Article Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis.

  2016cites this paper
• Pharmacogenetics of Serious Antipsychotic Side Effects

  2016cites this paper
• Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation

  2016cites this paper
• The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk

  2016cites this paper
• Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes

  2016cites this paper
• Genetics of Common Antipsychotic-Induced Adverse Effects

  2016cites this paper
• Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations

  2016cites this paper
• Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis

  2016cites this paper
• COMT val158met moderation of dopaminergic drug effects on cognitive function: A critical review

  2016cites this paper
• Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations

  2016cites this paper
• [Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].

  2015influential citation
• Clinical implications of neuropharmacogenetics.

  2015cites this paper
• The Role of Abcb5 Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans

  2015cites this paper
• Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia

  2015cites this paper
• Фармакогенетический подход к оценке риска развития индуцированных антипсихотиками экстрапирамидных нарушений

  2015cites this paper
• The Role of Abcb 5 Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans

  2015cites this paper
• Identification and management of tardive dyskinesia: A case series and literature review

  2015cites this paper
• Movement Disorders and Psychosis, a Complex Marriage

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Pharmacogenetics of Adverse Events in Schizophrenia Treatment: Comparison Study of Ziprasidone, Olanzapine and Perazine

  2014cites this paper
• Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia.

  2014cites this paper
• Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight

  2014cites this paper
• Pharmacogenetics of Antipsychotics

  2014cites this paper
• Pharmacogenetics of antipsychotic treatment in schizophrenia.

  2014cites this paper
• Pharmacogenetics in the Treatment of Schizophrenia

  2014cites this paper
• A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs by D. G. Cunningham Owens

  2014cites this paper
• Individual Differences in Neural Reward and Threat Processing: Identifying Pathways of Risk and Resilience for Psychopathology

  2014cites this paper
• ОКИСЛИТЕЛЬНЫЙ СТРЕСС И ГЛУТАМАТЕРГИЧЕСКАЯ ЭКСАЙТОТОКСИЧНОСТЬ В РАЗВИТИИ ЛЕКАРСТВЕННО-ИНДУЦИРОВАННОЙ ТАРДИВНОЙ ДИСКИНЕЗИИ

  2014cites this paper
• BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

  2014influential citation
• Pharmacogenetics in major depression: a comprehensive meta-analysis.

  2013influential citation
• Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.

  2013cites this paper
• Association of the dopamine β‐hydroxylase 19 bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia

  2013influential citation
• Association polymorphic variants of GRIN2B gene with paranoid schizophrenia and response to typical neuroleptics in Russians and Tatars from Bashkortostan Republic

  2013cites this paper
• Personalized medicine in psychiatry: problems and promises

  2013cites this paper
• Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study

  2013influential citation
• Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

  2013cites this paper
• Polymorphism of RGS2 gene as genetic marker of schizophrenia risk and pharmacogenetic markers of the efficiency of typical neuroleptics

  2013cites this paper
• Deep Brain Stimulation of the Subthalamic and Entopeduncular Nuclei in an Animal Model of Tardive Dyskinesia

  2013cites this paper
• The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol

  2013cites this paper
• Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia.

  2013cites this paper
• There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients

  2013cites this paper
• Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.

  2013cites this paper
• A genetic dissection of antipsychotic induced movement disorders.

  2013cites this paper
• An Update on Tardive Dyskinesia: From Phenomenology to Treatment

  2013cites this paper
• INFLUÊNCIA DA FARMACOGENÓMICA NA TERAPÊUTICA COM ANTIPSICÓTICOS EM DOENTES ESQUIZOFRÉNICOS

  2013cites this paper
• Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for CYP1A2

  2012cites this paper
• Analysis of PARK2 gene exon rearrangements in Russian patients with sporadic Parkinson's disease

  2012cites this paper
• Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis

  2012cites this paper
• Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms.

  2012cites this paper
• Pharmacogenetics of Drug Targets

  2012cites this paper